Disease activity and cognition in rheumatoid arthritis: An open label pilot study

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Raftery, Graham ^a   He, Jiabao ^b   Pearce, Ruth ^b   Birchall, Daniel ^c   Newton, Julia L ^b   Blamire, Andrew M ^b   Isaacs, John D ^b,d  

^a CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Neuroradiology Department   (United Kingdom)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DISEASE ACTIVITY; FATIGUE; FEMALE; GRAY MATTER; HUMAN; INTELLIGENCE QUOTIENT; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PILOT STUDY; PSYCHOMETRY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WHITE MATTER; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BRAIN CIRCULATION; DRUG EFFECTS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; WECHSLER INTELLIGENCE SCALE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CEREBROVASCULAR CIRCULATION; COGNITION; FATIGUE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ANALOG SCALE; WECHSLER SCALES;

EID: 84870344600     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4108     Document Type: Article

References (14)

1. Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A, Hughes R. Outcomes generated by patients with rheumatoid arthritis: how important are they?. Musculoskeletal Care 2005, 3:131-142. 10.1002/msc.3, 17042002.
2. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, Hehir M. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005, 53:697-702. 10.1002/art.21450, 16208668.
3. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:838-846.
4. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45. 10.1186/1742-2094-5-45, 2577641, 18925972.
5. Sibson NR, Blamire AM, Perry VH, Gauldie J, Styles P, Anthony DC. TNF-alpha reduces cerebral blood volume and disrupts tissue homeostasis via an endothelin- and TNFR2-dependent pathway. Brain 2002, 125:2446-2459. 10.1093/brain/awf256, 12390971.
6. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, Weisman MH. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008, 59:332-337. 10.1002/art.23308, 18311758.
7. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med 1995, 34:293-301. 10.1002/mrm.1910340303, 7500865.
8. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal Rheumatol 2005, 32:811-819.
9. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: A general linear approach. Human Brain Mapping 1995, 2:189-210.
10. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000, 47:93-100. 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.0.CO;2-8, 10632106.
11. Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheumatoid arthritis. Methods Find Exp Clin Pharmacol 2004, 26:339343.
12. Bartolini M, Candela M, Brugni M, Catena L, Mari F, Pomponio G, Provinciali L, Danieli G. Are behaviour and motor performances of rheumatoid arthritis patients influenced by subclinical cognitive impairments? A clinical and neuroimaging study. Clin Exp Rheumatol 2002, 20:491-497.
13. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5, 18358926.
14. Heiberg T, Mowinckel P, Kvien T, Hagen K. Patterns of symptom variation: is level of fatigue independent of pain intensity in individual patients with rheumatoid Arthritis (RA)?. Ann Rheum Dis 2009, 68(Suppl3):149.